Literature DB >> 19275796

Potentially preventable tuberculosis among HIV-infected persons in the era of highly active antiretroviral treatment.

A C Pettit1, G Barkanic, S Stinnette, P Rebeiro, R Blackwell, S P Raffanti, B E Shepherd, T R Sterling.   

Abstract

OBJECTIVE: To characterize the proportion of tuberculosis (TB) cases that could have been prevented among human immunodeficiency virus (HIV) infected persons receiving care in the era of highly active antiretroviral treatment (HAART).
DESIGN: We conducted an observational cohort study among HIV-infected patients with >or=2 out-patient visits at the Comprehensive Care Center, Nashville, Tennessee, USA, between 1 January 1998 and 31 December 2005.
METHODS: A potentially preventable TB case was defined as a case in which the patient received no screening tuberculin skin test (TST) prior to TB diagnosis or a case in which a patient with a positive screening TST did not complete treatment for latent infection.
RESULTS: Of 3601 HIV-infected persons in care (13 905 person-years [p-y] of follow-up), 29 developed TB (230/100,000 p-y). Of the 29, 20 (69%) had not had TST performed as part of routine screening. Of the nine patients screened, four had a positive test, three of whom completed treatment for latent TB infection. Of 29 TB cases, 21 (72%) were therefore potentially preventable.
CONCLUSIONS: Most TB cases in this cohort were potentially preventable had the patients undergone a screening TST followed by treatment of latent infection if they had a positive TST.

Entities:  

Mesh:

Year:  2009        PMID: 19275796      PMCID: PMC2866056     

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  12 in total

Review 1.  Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals.

Authors:  Stephen D Lawn; Linda-Gail Bekker; Robert F Miller
Journal:  Lancet Infect Dis       Date:  2005-06       Impact factor: 25.071

2.  A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection.

Authors:  P A Selwyn; D Hartel; V A Lewis; E E Schoenbaum; S H Vermund; R S Klein; A T Walker; G H Friedland
Journal:  N Engl J Med       Date:  1989-03-02       Impact factor: 91.245

3.  Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission.

Authors:  Luigia Elzi; Matthias Schlegel; Rainer Weber; Bernard Hirschel; Matthias Cavassini; Patrick Schmid; Enos Bernasconi; Martin Rickenbach; Hansjakob Furrer
Journal:  Clin Infect Dis       Date:  2006-11-28       Impact factor: 9.079

4.  Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America.

Authors:  Enrico Girardi; Caroline A Sabin; Antonella d'Arminio Monforte; Bob Hogg; Andrew N Phillips; M John Gill; Francois Dabis; Peter Reiss; Ole Kirk; Enos Bernasconi; Sophie Grabar; Amy Justice; Schlomo Staszewski; Gerd Fätkenheuer; Jonathan A C Sterne
Journal:  Clin Infect Dis       Date:  2005-11-11       Impact factor: 9.079

5.  Detection of latent tuberculosis among HIV-infected patients after initiation of highly active antiretroviral therapy.

Authors:  Tamara L Fisk; Hui-Ming Hon; Jeffrey L Lennox; C Fordham von Reyn; C Robert Horsburgh
Journal:  AIDS       Date:  2003-05-02       Impact factor: 4.177

6.  The scope and impact of treatment of latent tuberculosis infection in the United States and Canada.

Authors:  Timothy R Sterling; James Bethel; Stefan Goldberg; Paul Weinfurter; Lourdes Yun; C Robert Horsburgh
Journal:  Am J Respir Crit Care Med       Date:  2006-01-19       Impact factor: 21.405

7.  Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society.

Authors: 
Journal:  MMWR Recomm Rep       Date:  2000-06-09

8.  Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research.

Authors:  Dick Menzies; Madhukar Pai; George Comstock
Journal:  Ann Intern Med       Date:  2007-03-06       Impact factor: 25.391

9.  Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.

Authors:  Scott M Hammer; Joseph J Eron; Peter Reiss; Robert T Schooley; Melanie A Thompson; Sharon Walmsley; Pedro Cahn; Margaret A Fischl; Jose M Gatell; Martin S Hirsch; Donna M Jacobsen; Julio S G Montaner; Douglas D Richman; Patrick G Yeni; Paul A Volberding
Journal:  JAMA       Date:  2008-08-06       Impact factor: 56.272

10.  Low adherence to guidelines for preventing TB among persons with newly diagnosed HIV infection, United States.

Authors:  L M Lee; M N Lobato; S E Buskin; A Morse; O S Costa
Journal:  Int J Tuberc Lung Dis       Date:  2006-02       Impact factor: 2.373

View more
  3 in total

1.  Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting?

Authors:  April C Pettit; Cathy A Jenkins; Samuel E Stinnette; Peter F Rebeiro; Robert B Blackwell; Stephen P Raffanti; Bryan E Shepherd; Timothy R Sterling
Journal:  J Acquir Immune Defic Syndr       Date:  2011-08-01       Impact factor: 3.731

2.  Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening.

Authors:  Timothy R Sterling; Bryan Lau; Jinbing Zhang; Aimee Freeman; Ronald J Bosch; John T Brooks; Steven G Deeks; Audrey French; Stephen Gange; Kelly A Gebo; M John Gill; Michael A Horberg; Lisa P Jacobson; Gregory D Kirk; Mari M Kitahata; Marina B Klein; Jeffrey N Martin; Benigno Rodriguez; Michael J Silverberg; James H Willig; Joseph J Eron; James J Goedert; Robert S Hogg; Amy C Justice; Rosemary G McKaig; Sonia Napravnik; Jennifer Thorne; Richard D Moore
Journal:  J Infect Dis       Date:  2011-09-15       Impact factor: 5.226

3.  Preventing nosocomial MDR TB transmission in sub Saharan Africa: where are we at?

Authors:  Sonia Menon
Journal:  Glob J Health Sci       Date:  2013-05-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.